ArticleScientific reports2025
Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated Computational Modeling Reveals a Structurally Plausible Transient Paclitaxel-NK2R Interaction.Bioengineering (Basel, Switzerland) · 2026Article
- Experimental Models and Nanotechnology-Based Platforms in Oral Squamous Cell Carcinoma: From Tumor Biology to Translational Applications.Pharmaceutics · 2026Review
- Integrated pharmacovigilance assessment of drug-associated cholangitis: signal detection, clinical characterization, and mechanistic insights.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nab-paclitaxel (albumin-bound paclitaxel) and traditional paclitaxel are both used in pancreatic cancer treatment, but their adverse event (AE) profiles may differ due to formulation differences. This study compares the safety profiles of Nab-paclitaxel and paclitaxel using the FDA Adverse Event Reporting System (FAERS) database. FAERS data from Q1 2004 to Q2 2024 were analyzed using disproportionality methods, including Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR), to detect significant AE signals. Adverse events were categorized by system organ classes, and key signals were identified and compared for each drug. Nab-paclitaxel was associated with a higher frequency of severe hematologic and hepatobiliary events, including neutropenia (ROR 44.63; PRR 23.86) and cholangitis (ROR 113.06). Additionally, Nab-paclitaxel had 539 reports of death (27.08%), while paclitaxel had 272 (9.68%). Paclitaxel was more frequently associated with infusion-related hypersensitivity reactions, with 172 cases of flushing and 116 hypersensitivity reactions. Time trends showed a steady increase in Nab-paclitaxel-related AEs, especially hematologic toxicities, suggesting greater risk accumulation over time. Nab-paclitaxel's nanoparticle formulation, while enhancing distribution and clearance properties, is linked to elevated hematologic and hepatic AEs in pancreatic cancer treatment, requiring vigilant patient monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.